NM_000311.5(PRNP):c.598G>A (p.Glu200Lys)

For PRNP c.598G>A (p.Glu200Lys), the most common genetic prion disease variant worldwide, intrathecal ASO-mediated PrP reduction (ION717, Ionis) represents the most advanced therapeutic strategy. The principle is that prion diseases require PrP substrate — reducing total PrP protein levels via RNase H-mediated mRNA degradation should slow or prevent prion propagation. The E200K variant is particularly amenable to this approach because of its relatively predictable age-of-onset distribution (typically 50-70 years) enabling identification and treatment of at-risk mutation carriers before symptom onset.

E200K is the most prevalent genetic prion disease variant, concentrated in Libyan Jewish, Slovakian, and Chilean kindreds, with ~60-90% lifetime penetrance. It causes a spectrum from classic CJD to fatal insomnia depending on the codon 129 polymorphism on the cis allele (Met favoring insomnia phenotype, Val favoring CJD). Raymond et al. demonstrated that PRNP-targeting ASOs extend survival in prion-infected mice by 61-98% when administered before symptoms (PMID:31587955). ION717 entered a Phase 1/2a trial for PRNP mutation carriers, measuring CSF PrP as a pharmacodynamic biomarker. Minikel et al. (PMID:33268508) established that naturally occurring heterozygous PRNP loss-of-function occurs in healthy humans, supporting the safety of ~50% PrP reduction. The pre-symptomatic treatment window for E200K is substantial: genetically at-risk individuals can be identified decades before expected symptom onset through family screening and genetic testing, enabling prophylactic ASO administration.

Once symptomatic prion neurodegeneration is established, PrP lowering may be insufficient to halt progression — the key therapeutic value is in pre-symptomatic prevention. This requires presymptomatic genetic testing, which raises profound ethical and psychological issues, particularly for a fatal disease with incomplete penetrance. Lifelong repeated intrathecal dosing (every 3-6 months) is required, as ASO effects are not permanent. The degree of PrP reduction needed for protection is uncertain; mouse data suggest >80% reduction is needed for survival benefit, but achieving this level safely in humans is unproven. E200K penetrance is incomplete (~60-90%), meaning some treated carriers would never have developed disease. The distinction between the CJD and insomnia phenotypes of E200K (influenced by codon 129 cis genotype) may affect clinical trial design and endpoint selection. ION717 trial results have not been published.